Improving drug use: A case study of events which led to changes in use of flucloxacillin in Australia

Social Science and Medicine

Volumn 48, Issue 6, 1999, Pages 845-853

  Roughead, Elizabeth E ^a   Gilbert, Andrew L ^a   Primrose, John G ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Cmw Dept of Health and Aged Care ^*  (Australia)

Author keywords

Adverse; Drug; Improving; Medication; Quality; System

Indexed keywords

FLUCLOXACILLIN;

ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTERIAL INFECTION; DRUG USE; HEALTH PROMOTION; HUMAN; TREATMENT PLANNING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AUSTRALIA; CEPHALEXIN; CEPHALOSPORINS; DRUG AND NARCOTIC CONTROL; DRUG UTILIZATION; FLOXACILLIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HEPATITIS, TOXIC; HUMANS; MODELS, PSYCHOLOGICAL; PENICILLINS; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG;

EID: 0033021275     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(98)00405-5     Document Type: Article

References (35)

1. ADRAC, 1990a. Flucloxacillin hepatitis. Aust. Adv. Drug React. Bull. 9 Feb, 2.
2. ADRAC, 1990b. Drug induced liver disease. Aust. Adv. Drug React. Bull. 9 Nov, 14.
3. ADRAC, 1992a. Update of flucloxacillin-induced hepatitis. Aust. Adv. Drug React. Bull. 11 Feb, 3.
4. ADRAC, 1992b. Drug-induced cholestatic hepatitis from common antibiotics. Med. J. Aust. 157, 531.
5. ADRAC, 1994. Fatal hepatic reactions to flucloxacillin. Aust. Adv. Drug React. Bull. 13 Aug, 10-11.
6. AIHW, 1997. Medical Labour Force 1995. AIHW Cat. No. HWL 5. National Health Labour Force Series No. 10. Australian Institute of Health and Welfare, Canberra.
7. Bandura, A., 1986. Social Foundations of Thought and Action: a Social Cognitive Theory. Prentice-Hall, Englewood Cliffs, NJ.
8. Barnard, A., Kamien, M., 1994. The reading habits of RACGP training program doctors. Aust. Fam. Phys. 23, 1752-1760.
9. Birkett, D.J., Mitchell, A.S., Godeck, A., Grigson, T., Cully, R., Lee, C., 1991. Profiles of antibacterial use in Australia and trends from 1987 to 1989: a report from the Drug Utilisation Subcommittee of the Pharmaceutical Benefits Advisory Committee. Med. J. Aust. 155, 410-415.
10. Bloom, W., 1993. Australian Prescriber Readership and Attitudes in 1993. A Report on a Two-part Survey, Qualitative and Quantitative. Conducted on behalf of the Executive Editorial Board, Australian Prescriber. Lenehan Lynton Bloom Blaxland Marketing and Communication Research, North Sydney.
11. Davis, D.A., Thomson, M.A., Oxman, A.D., Haynes, R.B., 1992. Evidence for the effectiveness of CME: a review of 50 randomized controlled trials. JAMA 268, 1111-1117.
12. Department of Community Service and Health, 1990. Schedule of Pharmaceutical Benefits, December 1990. Government Printer, Canberra.
13. Department of Health, Housing and Community Services, 1992. The Policy on the Quality Use of Medicines. Prepared in conjunction with The Pharmaceutical Health and the Rational use of Medicines (PHARM) Working Party, Canberra.
14. Department of Human Services and Health, 1993. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners, August 1993. Australian Government Publishing Service, Canberra.
15. Department of Human Services and Health, 1994. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners, August 1994. Australian Government Publishing Service, Canberra.
16. Derby, A.L., Jick, H., Henry, D.A., Dean, A.D., 1993. Cholestatic hepatitis associated with flucloxacillin. Med. J. Aust. 158, 596-600.
17. Devereaux, B.M., Crawford, D.H.G., Purcell, P., Powell, L.W., Roeser, H.P., 1995. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur. J. Clin. Pharmacol. 49, 81-85.
18. Edmonds, D.J., Dumbrell, D.M., Primrose, J.G. et al, 1993. Development of an Australian drug utilisation database: a report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. PharmacoEconomics 3, 427-432.
19. Fairley, C.K., McNeill, J.J., Desmond, P.V. et al, 1993. Risk factors for development of flucloxacillin associated jaundice. Br. Med. J. 306, 233-235.
20. Glaser, S., Ash-Young, L., 1984. A Survey of Aspects of the Monitoring of the Safety of Drugs. A Report for the Adverse Drug Reactions Advisory Committee. School of Marketing, The University of New South Wales.
21. Green, L.W., Kreuter, M.W., 1992. CDC's planned approach to community health as an application of Precede and an inspiration for Proceed. J. Health Ed. 23, 140-147.
22. Gupta, L., Ward, J.E., Hayward, R.S.A., 1997. Clinical practice guidelines in general practice: a national survey of recall, attitudes and impact. Med. J. Aust. 166, 69-72.
23. Jick, H., Derby, L.E., Dean, A.D., Henry, D.A., 1994. Flucloxacillin and cholestatic hepatitis (Letter). Med. J. Aust. 160, 525.
24. Laing, R., Ross-Degnan, D., Lamoureux, C., 1997. Interventions to improve use of medicines in hospitals in developing countries. Paper presented at the International Conference on Improving Use of Medicines, Chiang Mai, Thailand, April 1-4.
25. McManus, P., Hammond, M.L., Whicker, S.D., Primrose, J.G., Mant, A., Fairall, S.R., 1997. Antibiotic use in the Australian community, 1990-1995. Med. J. Aust. 167, 124-127.
26. Prochaska, J.O., Di Clemente, C.O., 1986. Towards a comprehensive model of change. In: Miller, W.R., Heather, N. (Eds.), Treating Addictive Behaviours: Processes of Change. Plenum Press, New York, pp. 3-27.
27. Prochaska, J.O., Velicer, W.F., Rossi, J.S. et al, 1994. Stages of change and decisional balance for 12 problem behaviours. Health Psych. 13, 39-46.
28. Roeser, H.P., Rohan, A.P., 1990. Post-marketing surveillance of drugs. The spontaneous reporting scheme: role of the Adverse Drug Reactions Advisory Committee. Med. J. Aust. 153, 720-726.
29. Soumerai, S.B., McLaughlin, T.J., Avorn, J., 1989. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q. 67, 268-317.
30. Turner, I.B., Eckstein, R.P., Riley, J.W., Lunzer, M.R., 1989. Prolonged hepatic cholestasis after flucloxacillin therapy. Med. J. Aust. 151, 701-705.
31. Turnidge, J., 1995. What to use instead of flucloxacillin. Aust. Prescriber 18 (3), 54-55.
32. VMPF Therapeutics Committee, 1996. Antibiotic Guidelines, ed. 9 1996/97. VMPF Therapeutics Committee, North Melbourne.
33. Winett, R.A., 1995. A framework for health promotion and disease prevention programs. Am. Psych. 50, 341-350.
34. Winett, R.A., King, A.C., Altman, D.G., 1989. Health Psychology and Public Health: an Integrative Approach. Pergamon Press, New York.
35. WHO, 1995. Guidelines for Developing National Drug Policies (draft final text 23 June). World Health Organisation, Geneva.